/PRNewswire/ DelveInsight s Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices,.
Nike founder Phil Knight gives $75M to Stanford to look at Alzheimer s, Parkinson s and brain resilience bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Share this article
LAS VEGAS, March 17, 2021 /PRNewswire/ DelveInsight s
Wet Age-Related Macular Degeneration (Wet AMD) Market report provides a thorough comprehension of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology, and the Wet AMD market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the vital points of the
The introduction of Anti-vascular endothelial growth factor (VEGF) as a standard Wet AMD treatment has led to a significant improvement in patients prognosis, allowing recovery and maintenance of visual function in the vast majority of cases.
Kenketu Glovenin-I in November 2015. The
corticosteroid prednisolone was authorized in some EU countries for the Bullous Pemphigoid treatment.
Prominent players such as
Akari Therapeutics, Immune Pharmaceuticals, iCo Therapeutics, Regeneron Pharmaceuticals, Sanofi,
Nihon Pharmaceutical, Innate Pharma, AstraZeneca, Alkahest, Inc., Grifols, and others are involved in developing Bullous Pemphigoid therapies. These companies hold the potential to create a significant positive shift in Bullous Pemphigoid market size.
Bullous Pemphigoid pipeline possesses potential drugs in mid and late-stage developments to be approved shortly. Certain emerging therapies such as
Dupilumab, Nomacopan, Bertilimumab (iCo-008), Avdoralimab (IPH5401), Fasenra (benralizumab), AKST4290, and many others are in the clinical trials and have shown better efficacious results in Bullous Pemphigoid patients.